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The Editorial on the Research Topic
Glycosylation Changes in Cancer: An Innovative Frontier at the Interface of Cancer and 
Glycobiology
Over the last 10 years, important discoveries have been made in the individual disciplines of glyco-
science, which have contributed to the deciphering of numerous human diseases, particularly the 
different types of cancer. It is well documented that malignant transformation and cancer progres-
sion result in fundamental changes in the glycosylation patterns of cell surface glycoconjugates. 
Such changes are able to govern essential molecular phenomena in cell biology. Examples include 
(i) cell signaling pathways, (ii) cell–cell and/or cell-extracellular matrix (ECM) interactions, (iii) 
cell invasion, (iv) tumor angiogenesis, (v) immunomodulation, and (vi) metastasis formation. The 
research topic “Glycosylation Changes in Cancer: An Innovative Frontier at the Interface of Cancer 
and Glycobiology” provides invaluable information on the exciting field of oncoglycobiology, where 
one original research and outstanding reviews are presented.
In their original article, Mihalache et  al. addressed the differential expression of mucins and 
the expression level of the major O-linked glycans in human colorectal cancer (CRC). The authors 
described differences in mucin glycosylation between CRC of various stages in order to propose new 
predictive or prognostic biomarkers.
Kolbl et al. discussed changes in the glycosylation pattern in breast cancer. The authors proposed 
that such aberrant glycan structures expressed by transformed breast cancer cells might be useful 
for diagnosis, determination of tumor stage, and prognosis but can as well be targets for therapeutic 
strategies.
In their opinion article, Nagarajan et al. highlighted the mechanisms by which heparin sulfate 
proteoglycans (HSPGs), such as glypicans, syndecans, and perlecans, are able to modulate tumor 
growth and metastasis.
Daniotti et al. provided a general overview on the metabolism of glycolipids, both in normal and 
tumor cells, as well as examining glycolipid-mediated immune modulation and the main successes 
achieved in immunotherapies using gangliosides as molecular targets.
Baldini and Lefebvre discussed about the reciprocal regulation of enzymes that drive lipogenesis 
(acetyl co-enzyme A carboxylase and fatty acid synthase) and O-GlcNAc transferase. In this perspec-
tive article, the authors pave the way for the exploration of the intricate functions of these actors that 
play a central role in tumor growth and spreading.
Li et al. summarized how glycans might influence cancer cells undergoing epithelial– mesenchymal 
transition (EMT), a biological process that allows a polarized epithelial cell, which normally interacts 
with basement membrane via its basal surface, to undergo multiple biochemical changes that enable 
it to assume a mesenchymal cell phenotype. Examples include (i) enhanced migratory capacity, 
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(ii)  invasiveness, (iii) elevated resistance to apoptosis, and (iv) 
greatly increased production of ECM components.
Pakkiriswami et  al. outlined recent advances in our under-
standing of glycosylation of Notch proteins and the impact of 
altered Notch glycans in promoting tumorigenesis and metasta-
sis. The authors defend the hypothesis that a full understanding 
of how atypical glycan structures affect Notch function requires 
further analysis. Methods need to be developed to examine how 
such changes in glycosylation temporally and spatially modulate 
cancer progression.
Mereiter et al. presented an overview on the main glycosylation 
changes in gastrointestinal cancers and the role of glycosylation 
as a modulator of the function of several key players in cancer 
cell biology. The authors also addressed several state-of-the-art 
techniques currently applied in this field, such as glycomic and 
glycoproteomic analyses, and provided an outlook to future 
perspectives and clinical applications.
Nardy et  al. addressed how tumor-associated carbohydrate 
antigens (TACAs) confer to the cancer cells, the ability of dis-
semination by escaping the immunesurveillance, and thereby 
affect cancer progression.
Sindrewicz et  al. summarized the current understanding 
concerning the molecular mechanisms underlying increased 
expression of the oncofetal Thomsen–Friedenreich disaccharide 
Galβ1-3GalNAc (TF antigen) in cancer, especially the structural 
nature and biological impact of TF interaction with galectins, in 
particular galectin-1 and galectin-3, on cancer progression and 
metastasis.
In their review article, Natoni et al. proposed that the inhi-
bition of selectin–selectin ligand interactions might be useful 
to improve the treatment of cancer patients. However, the 
consequence of this strategy will depend on the type of cancer 
and the stage at diagnosis. Strategically, the authors suggest that 
the impairment of selectin/selectin ligand interactions may be 
achieved by the inhibition of key enzymes responsible for gen-
erating the selectin ligands, such as sialyltransferases (STs), or 
blockage of selectin/selectin ligands interactions by the use of a 
variety of compounds, such as glycomimetics, heparin deriva-
tives, and blocking antibodies.
Taparra et al. reviewed the potential role of the hexosamine 
biosynthetic pathway (HBP) in driving EMT-related cancer 
processes. The authors believe that expanding the knowledge 
of how changes in metabolic pathways observed in cancer (e.g., 
the HBP) impact the distribution and composition of glycocon-
jugates may provide deeper insights into mechanisms of cancer 
biology.
Cagnoni et al. addressed the current status of the discovery and 
development of chemical lectin inhibitors and discussed novel 
strategies to limit cancer progression by targeting lectin–glycan 
interactions. In addition, the authors outlined the importance 
of understanding the biochemistry, biology, and glycobiology 
involved in tumor development and progression. They claim 
that the major challenge faced by this field is designing selective 
inhibitors of lectin–glycan interactions with increased bioavail-
ability, what would improve cancer treatments.
Cardoso et  al. highlighted the impact of galectin–glycan 
interactions in the tumor microenvironment, especially about 
the way that galectin-3 may participate in the activation of 
mitogen-activated protein kinases (MAPK) signal transduction 
pathways, leading to cancer cell proliferation, and resistance to 
apoptosis.
Finally, Fonseca et  al. proposed that glycosylation changes 
in cancer cells might connect the multidrug resistance (MDR) 
phenotype and the EMT process, two multifactorial events able to 
modulate cancer cell half-life and tumor growth and metastasis.
Taken together, all articles published in this research topic 
reinforce the notion that oncoglycobiology is an important 
biological and medical field, and further research in this lively 
area may render valuable information, which might be used for 
therapeutic and diagnostic purposes.
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